Setmelanotide
RM-493-022
Phase 3 small_molecule active
Quick answer
Setmelanotide for Obesity Associated With Defects in Leptin-melanocortin Pathway is a Phase 3 program (small_molecule) at Rhythm Pharmaceuticals Netherlands B.V. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Rhythm Pharmaceuticals Netherlands B.V.
- Indication
- Obesity Associated With Defects in Leptin-melanocortin Pathway
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active